AnGes MG Inc. | Cash Flow

Fiscal year is January-December. All values JPY Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
1,402,184.00
2,357,614.00
4,124,150.00
4,760,670.00
3,744,187.00
3,003,002
Depreciation, Depletion & Amortization
60,117.00
45,947.00
48,983.00
67,306.00
29,352.00
7,860
Other Funds
15,586.00
-
-
26,371.00
84,200.00
58,990
Funds from Operations
1,320,889.00
2,204,956.00
4,045,775.00
4,686,687.00
2,995,430.00
3,054,130
Changes in Working Capital
135,748.00
498,668.00
549,965.00
297,007.00
4,207.00
531,629
Net Operating Cash Flow
1,456,637.00
2,703,624.00
4,595,740.00
4,983,694.00
2,991,223.00
2,522,501
Capital Expenditures
14,780.00
18,332.00
63,617.00
70,995.00
9,272.00
Purchase/Sale of Investments
4,886.00
103,748.00
9,430.00
758,819.00
236,334.00
Net Investing Cash Flow
27,203.00
52,082.00
73,047.00
829,815.00
227,062.00
Net Financing Cash Flow
3,389,880.00
6,426,732.00
716,713.00
4,793,388.00
2,916,035.00
Net Change in Cash
1,940,374.00
3,716,175.00
3,942,504.00
1,073,204.00
152,133.00
Free Cash Flow
1,466,587.00
2,718,136.00
4,641,108.00
5,033,239.00
2,998,255.00
Net Assets from Acquisitions
16,351.00
-
-
-
-
Other Sources
13,619.00
69,998.00
-
-
-
Change in Capital Stock
3,374,294.00
6,426,732.00
716,713.00
4,767,017.00
2,831,835.00
Exchange Rate Effect
34,334.00
45,149.00
9,570.00
53,083.00
259.00
Other Uses
4,805.00
-
-
-
-

About AnGes MG

View Profile
Address
Saito Bio-Incubator 1F
Osaka Osaka 567
Japan
Employees -
Website http://www.anges.co.jp
Updated 07/08/2019
AnGes, Inc. engages in the research and development of gene-based medical products. It offers genetic medicines such as hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, and others. It is also involved in the research and development of medical equipment, which improves blood circulation by regenerating blood vessels and NfkB which controls various inflammations.